查詢結果分析
相關文獻
- 晚期非小細胞肺癌藥物治療現況與未來發展
- Recent Advances in Systemic Therapy for Non-Small Cell Lung Cancer in Elderly Patients
- 非小細胞肺癌的維持性治療
- Patients Who Previously Responded to EGFR-TKI Treatment with Progression Responded to a Second EGFR-TKI Treatment after Challenge with Chemotherapy
- 非小細胞肺癌標靶治療現況
- 非小細胞肺癌標靶藥物治療新進展
- Gefitinib as First-Line Therapy for Advanced or Metastatic Non-Small Cell Lung Cancer Patients in Southern Taiwan
- Bortezomib-induced Apoptosis in the Treatment of Non-small Cell Lung Cancer
- 晚期非小細胞肺癌的標靶治療
- 非小細胞肺癌治療之風雲再起
頁籤選單縮合
題 名 | 晚期非小細胞肺癌藥物治療現況與未來發展=Current Drug Therapy and Future Development in Advanced Non-Small Cell Lung Cancer |
---|---|
作 者 | 鄭婷方; 鄭吉元; 陳琦華; 鄧新棠; | 書刊名 | 藥學雜誌 |
卷 期 | 28:1=110 2012.03[民101.03] |
頁 次 | 頁93-97 |
分類號 | 418.31 |
關鍵詞 | 非小細胞肺癌; 標靶治療; 維持治療; Non-small cell lung cancer; Targeted therapy; Maintenance therapy; |
語 文 | 中文(Chinese) |
中文摘要 | 將近70%的非小細胞肺癌病人在診斷時已為局部晚期或轉移,而無法手術治療。針對晚期 NSCLC,目前化學治療的效果仍十分有限。近期許多的治療策略,包含標靶治療、化療合併標靶治療、長期的維持治療,均顯示其療效及耐受性。對於晚期 NSCLC 藥物治療的選擇,我們必須要瞭解年齡、身體功能狀態、種族差異性以及腫瘤組織學型態都是相當重要的決定因子。隨著分子生物學和生物標記的進步,未來 NSCLC 的治療將進入個人化量身訂作的時代。 |
英文摘要 | Lung cancer is the leading cause of cancer death worldwide. Approximate 85% of lung cancer is non-small cell lung cancer (NSCLC). Around 70% of NSCLC patients are locally advanced or metastasis at first diagnosis, and can not do surgery. Although chemotherapy is very important for the treatment of NSCLC, most of patients have no good response to chemotherapy and the disease is still in progression. Recent therapy strategies, including targeted therapy, combination of chemotherapy and targeted therapy and maintenance therapy, have shown their efficacy and treatment tolerance for patients. Age, performance status, ethnic difference, and tumor histology are all important factors for the choice of drug treatment in advanced NSCLC. Through the achievements of molecular biology and biomarkers, the future treatment of NSCLC will be a tailored therapy individually. |
本系統中英文摘要資訊取自各篇刊載內容。